skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series



Case Series

(12324) Total Article Views


Authors: Keppel Hesselink JM, Hekker TA


Video abstract presented by Jan M Keppel Hesselink
Views: 636

Published Date October 2012 Volume 2012:5 Pages 437 - 442
DOI: http://dx.doi.org/10.2147/JPR.S32143

Jan M Keppel Hesselink, Thecla AM Hekker

Institute for Neuropathic Pain, Bosch en Duin, Netherlands

Abstract: Palmitoylethanolamide (PEA), an endogenous fatty acid amide, has been demonstrated to bind to a receptor in the cell nucleus – the peroxisome proliferator–activated receptor – and performs a great variety of biological functions related to chronic and neuropathic pain and inflammation, as has been demonstrated in clinical trials. These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia, and vaginal pains. Probably due to the fact that PEA is an endogenous modulator as well as a compound in food, such as eggs and milk, no serious side effects have been reported, nor have drug–drug interactions. This article presents a case series describing the application and potential efficacy and safety of PEA in the treatment of various syndromes associated with chronic pain that is poorly responsive to standard therapies.

Keywords: endocannabinoid, chronic, neuropathy, chemotherapy, itch, polyneuropathy



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Prof. Dr. Jan Keppel Hesselink


Readers of this article also read: